Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey

Istanbul University - Cerrahpasa (IUC)

Status: Completed

Conditions: Retinoblastoma

Treatments: Drug: intra-arterial administration of melphalan

Study type: Observational

Funder types: Other

Identifiers

NCT03935074

10136532

Details and patient eligibility

About

Retrospective review of 5-year long term outcomes of superselective intra-arterial chemotherapy treatment in retinoblastoma in a single institute.

The treatment outcomes, globe salvage rates and complications of superselective intra-arterial chemotherapy both for treating naive patients (primary treatment group) and for patients who received systemic chemotherapy previously (secondary treatment group) were evaluated.

Enrollment: 30 patients

Sex: All

Ages: 5 months to 7 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients diagnosed with unilateral/bilateral retinoblastoma

Exclusion criteria

• patients with trilateral retinoblastoma
• extraoculer involvement
• patients with blood dyscrasias, bleeding and clotting disorders

Trial design

30 participants in 2 patient groups

group 1

Description:

Patients who received intra-arterial chemotherapy as a first line treatment

Treatment:

Drug: intra-arterial administration of melphalan

group 2

Description:

Patients who received intra-arterial chemotherapy as a salvage treatment after systemic chemotherapy

Treatment:

Drug: intra-arterial administration of melphalan